Jul 17, 07
|
| NEW STORY |
| 20:22 ET |
Orchestra Therapeutics Discontinues Its HIV Vaccine Development Program
|
|
Jun 11, 07
|
| 07:00 ET |
Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax(TM) Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
|
|
May 24, 07
|
| 07:00 ET |
Orchestra Therapeutics to Present at Red Chip Small-Cap Investor Conference
|
|
Apr 16, 07
|
| 04:00 ET |
Orchestra Therapeutics Announces New Trading Symbol
|
|
Apr 04, 07
|
| 04:00 ET |
The Immune Response Corporation Announces Rebranding to Reflect Expanded Focus on Treatment of Autoimmune Diseases
|
|
Mar 07, 07
|
| 17:45 ET |
The Immune Response Corporation Injects First Patient in Trial of NeuroVax(TM) for Treatment of Multiple Sclerosis
|
|
Feb 28, 07
|
| 19:30 ET |
The Immune Response Corporation Extends Warrants Exercise Deadline
|
|
Feb 15, 07
|
| 08:00 ET |
The Immune Response Corporation's Interim Phase II Data Suggest Both REMUNE and IR103 Stabilize CD4+ Cell Counts in Drug-Naive HIV Patients
|
|
Jan 04, 07
|
| 19:00 ET |
The Immune Response Corporation Announces Receipt of Milestone Payment From NovaRx Corporation
|
|
Dec 20, 06
|
| 20:04 ET |
The Immune Response Corporation Announces New Trading Symbol as One-for-100 Reverse Stock Split Takes Effect
|
|
Dec 12, 06
|
| 09:00 ET |
The Immune Response Corporation to Present at New York Society of Security Analysts 10th Annual Biotech/Specialty Pharma Industry Conference
|
|
Dec 04, 06
|
| 09:00 ET |
The Immune Response Corporation to Present at the Wall Street Analyst Forum Biotechnology and Healthcare Conference
|
|
Nov 14, 06
|
| 17:00 ET |
The Immune Response Corporation Settles Shareholder Class Action Lawsuit
|
|
Nov 08, 06
|
| 17:00 ET |
Immune Response Corporation Extends Exercise Date for Warrants
|
|
Oct 26, 06
|
| 16:28 ET |
Spelman Research Initiates Coverage of The Immune Response Corporation With Price Target of $0.059 Per Share
|
|
Oct 11, 06
|
| 09:00 ET |
The Immune Response Corporation Releases Shareholder Update From President and CEO
|
|
Nov 17, 04
|
| 10:00 ET |
The Immune Response Corporation Presents Preliminary Analysis of REMUNE Phase II Trial in HIV Positive, Drug Naive Patients
|
|
Nov 16, 04
|
| 10:00 ET |
The Immune Response Corporation Announces the Addition of Dr. Bruce F. Mackler to Its HIV Scientific Advisory Board
|
|
Nov 03, 04
|
| 07:02 ET |
The Immune Response Corporation to Present at Capital Growth Investor Forum
|
|
Oct 21, 04
|
| 07:09 ET |
The Immune Response Corporation to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
|
|
Sep 28, 04
|
| 07:00 ET |
The Immune Response Corporation Announces REMUNE(R) Restores HIV-1-Specific Activity of CD4+ and CD8+ T Cells, Similar to Anti-HIV Immune Responses Seen in Long-Term Nonprogressors
|
|
Sep 14, 04
|
| 07:01 ET |
The Immune Response Corporation Presents New Phase II Clinical Data Indicating That REMUNE(R) Induces a HIV-Specific Immune Response
|
|
Sep 10, 04
|
| 07:00 ET |
The Immune Response Corporation Announces Clinical Trial for HIV Therapy IR103 Has Begun to Enroll
|
|
Sep 08, 04
|
| 07:01 ET |
The Immune Response Corporation and NovaRx Corporation Announce Revision of Licensing Agreement for Cancer Cell Line Vaccines
|
|
Jul 27, 04
|
| 10:00 ET |
The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103
|
|
Jul 15, 04
|
| 07:00 ET |
The Immune Response Corporation Presents Data Demonstrating IR103 HIV-Specific Immunologic Activity at XV International AIDS Conference
|
|
Jul 01, 04
|
| 07:01 ET |
The Immune Response Corporation Presents Preliminary Clinical Data, Further Demonstrating NeuroVax(TM) Immunological Activity, at European Neurological Society Meeting
|
|
Jun 15, 04
|
| 07:02 ET |
The Immune Response Corporation to Initiate First Clinical Study With IR103 in HIV Patients in a Multi-Center, International Clinical Trial
|
|
Jun 07, 04
|
| 07:02 ET |
The Immune Response Corporation Presents New Data on REMUNE(R) and IR103 Suggesting HIV-1 Specific Immune Responses
|
|
May 18, 04
|
| 07:03 ET |
The Immune Response Corporation Appoints David C. Mitchell as Executive Director, Regulatory Affairs
|
|
May 06, 04
|
| 20:00 ET |
The Immune Response Corporation to Present at Rodman & Renshaw Techvest Global Healthcare Conference
|
|
Apr 30, 04
|
| 07:01 ET |
The Immune Response Corporation Obtains $12 Million in Private Placement Financing
|
|
Apr 29, 04
|
| 07:10 ET |
The Immune Response Corporation's NeuroVax(TM) Demonstrates Strong Results in Phase I/II Study in Multiple Sclerosis
|
|
Apr 21, 04
|
| 21:55 ET |
The Immune Response Corporation Announces Three Abstracts Accepted at Two Prestigious International Scientific Conferences
|
|
| 07:08 ET |
The Immune Response Corporation Announces Four Abstracts Accepted at Two Prestigious International Scientific Conferences
|
|
Apr 14, 04
|
| 07:07 ET |
The Immune Response Corporation Presents Preclinical Results Supporting Continued Development of New HIV Product Candidate, IR103
|
|
Apr 06, 04
|
| 07:01 ET |
The Immune Response Corporation Announces Multiple Sclerosis Phase II Clinical Trial Under New Grant
|
|
Apr 05, 04
|
| 15:30 ET |
The Immune Response Corporation's Auditors Expressed a Going-Concern Qualification
|
|
Mar 30, 04
|
| 07:02 ET |
Canadian Clinical Trial Investigates REMUNE(R) as a Drug-Sparing Therapy in HIV-Positive Patients
|
|
Jan 07, 04
|
| 08:30 ET |
The Immune Response Corporation Converts $3.9 Million of Debt Plus Accrued Interest to Equity in Private Placement
|
|
Nov 18, 03
|
| 08:32 ET |
The Immune Response Corporation Progress Report at the NYSSA 7th Annual Health Care Industry Conference to be Webcast
|
|
Nov 03, 03
|
| 08:32 ET |
The Immune Response Corporation Initiates a Preclinical Development Program with IR103, a New Vaccine Candidate for the Prevention and Treatment of HIV
|
|
Oct 21, 03
|
| 08:33 ET |
The Immune Response Corporation to Provide Company Update at the Rodman & Renshaw Techvest Healthcare Conference
|
|
Oct 15, 03
|
| 08:30 ET |
The Immune Response Corporation Announces the Appointment of Michael K. Green as Vice President, Finance and Chief Financial Officer
|
|
Oct 14, 03
|
| 08:32 ET |
The Immune Response Corporation Enters into Agreements for $12.0 Million Private Placement Financing
|
|
Oct 09, 03
|
| 08:31 ET |
The Immune Response Corporation Licenses Hybridon's 2nd-Generation CpG DNA Adjuvant, AMPLIVAX(TM), for Use in Development of a Novel Vaccine for the Prevention and Treatment of HIV
|
|
Sep 29, 03
|
| 08:30 ET |
The Immune Response Corporation Initiates Phase II Study of REMUNE(R) With HIV-Infected Patients in Italy
|
|
Sep 18, 03
|
| 08:01 ET |
Webcast Alert: Immune Response Corporation Announces IMNR Presentation at Redchip Partners Fall New York Investor Conference 2003 Webcast
|
|
Sep 17, 03
|
| 08:31 ET |
The Immune Response Corporation Continues to Expand Its HIV/AIDS Expertise With the Appointment of Peter L. Salk, M.D., to Its Scientific Advisory Board
|
|
Sep 10, 03
|
| 08:31 ET |
The Immune Response Corporation Receives Approximately $3.2 Million in Gross Proceeds Through the Exercise of Class A Warrants
|
|
Aug 28, 03
|
| 03:20 ET |
The Immune Response Corporation Issues Notice Regarding The Redemption of Its Class A Warrants
|
|
Jan 13, 03
|
| 14:03 ET |
The Immune Response Corporation Announces Departure of President Dr. Ronald B. Moss
|
|
Dec 19, 02
|
| 08:45 ET |
The Immune Response Corporation Granted Patent in South Africa for Novel Formulation of REMUNE(R)
|
|
Dec 11, 02
|
| 18:48 ET |
The Immune Response Corporation Announces Completion of Private Offering of $8.4 Million
|
|
Nov 20, 02
|
| 18:19 ET |
The Immune Response Corporation Announces Third Quarter 2002 Financial Results
|
|
Oct 24, 02
|
| 09:31 ET |
The Immune Response Corporation Announces Extension of the Date by Which It Must Comply With Nasdaq SmallCap Listing Requirements
|
|
Oct 17, 02
|
| 09:15 ET |
The Immune Response Corporation Announces Study Suggesting Protection From HIV Infection and Induction of HIV-Specific Immune Responses Using REMUNE(R) Antigen With CpG ODN
|
|
Oct 08, 02
|
| 20:07 ET |
The Immune Response Corporation Announces Reverse Stock Split
|
|
Sep 09, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Restructuring and Cost Reductions To Focus Exclusively On REMUNE(R)
|
|
Aug 23, 02
|
| 11:44 ET |
The Immune Response Corporation Announces Second Quarter 2002 Financial Results
|
|
Aug 15, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Results From Trial of REMUNE(R) In Treatment Interruptions for Chronic HIV Infection
|
|
Aug 14, 02
|
| 20:53 ET |
The Immune Response Corporation Announces Selection Of BDO Seidman, LLP as New Auditing Firm
|
|
Jul 25, 02
|
| 07:02 ET |
** ATTENTION PLANNING EDITORS **
|
|
Jul 18, 02
|
| 07:08 ET |
The Immune Response Corporation Granted Patent For T-Cell Receptor Peptide Vaccine to Treat Psoriasis
|
|
Jul 11, 02
|
| 07:31 ET |
The Immune Response Corporation Announces Oral Presentation of Three Year Clinical Evaluation of REMUNE(R) at XIV World AIDS Conference in Barcelona
|
|
Jul 10, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Results of ACTG Clinical Trial Indicating REMUNE(R) Alone Stimulated Stronger Immune Responses Compared With REMUNE(R) Plus IL-2
|
|
Jul 09, 02
|
| 07:02 ET |
The Immune Response Corporation Announces Proposed Private Offering Of Common Stock and Warrants
|
|
Jul 08, 02
|
| 07:15 ET |
The Immune Response Corporation Announces Presentation of Study Results On REMUNE(R)'s Potential for Treating Chronically Infected HIV-Positive Patients
|
|
| 07:01 ET |
The Immune Response Corporation Announces Suspension of Reverse Stock Split And Intention to Apply for Nasdaq SmallCap Market Listing
|
|
Jul 02, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Significant Restructuring Of Trinity Medical Group License and Collaboration Agreement
|
|
Jun 26, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Bjorn K. Lydersen As Vice President of Manufacturing
|
|
Jun 20, 02
|
| 07:00 ET |
The Immune Response Corporation Names Michael L. Jeub As Chief Financial Officer
|
|
Jun 19, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Restructuring of Equipment Debt Arrangement
|
|
Jun 11, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Publication of Study Results For AIDS Preventive Vaccine Candidate for Developing Countries
|
|
May 30, 02
|
| 07:01 ET |
The Immune Response Corporation Releases Results for an AIDS Preventative Vaccine Candidate
|
|
May 21, 02
|
| 07:00 ET |
The Immune Response Corporation Announces First Quarter 2002 Financial Results
|
|
May 13, 02
|
| 07:00 ET |
Immunization With REMUNE(R) in Immunocompetent HIV-Infected Patients May Lead To Stronger Immune Responses and Possible Control of Viral Replication
|
|
May 07, 02
|
| 07:02 ET |
The Immune Response Corporation Announces Completion of a $4 Million Private Financing
|
|
Apr 30, 02
|
| 07:02 ET |
The Immune Response Corporation Receives Notification From Nasdaq
|
|
Apr 24, 02
|
| 07:01 ET |
The Immune Response Corporation Receives Milestone Payment From Licensee NovaRx Corporation
|
|
Apr 22, 02
|
| 07:01 ET |
The Immune Response Corporation Announces AstraZeneca and T Cell Sciences Have Unconditionally Withdrawn European Opposition To The Company's T Cell Receptor Peptide Patent
|
|
Apr 03, 02
|
| 07:02 ET |
The Immune Response Corporation Announces Result of Special Meeting of Stockholders
|
|
Apr 02, 02
|
| 07:01 ET |
The Immune Response Corporation Announces Fourth Quarter and Year End 2001 Financial Results
|
|
Mar 22, 02
|
| 07:00 ET |
The Immune Response Corporation Announces Completion of a $2 Million Private Financing
|
|
Feb 28, 02
|
| 07:01 ET |
Additional Data on REMUNE(R) From Spanish Phase II Trial STIR 2102 Presented At Ninth Conference on Retroviruses and Opportunistic Infections
|
|
Feb 27, 02
|
| 07:01 ET |
NeuroVax(TM) T Cell Receptor Peptide Based Vaccine Achieves Primary Endpoint in Phase I/II Multiple Sclerosis Trial
|
|
Feb 26, 02
|
| 07:02 ET |
Animal Study Suggests Intranasal Delivery of HIV-1 Antigen With Adjuvant May Induce Potent Immune Responses Capable of Protection Against Viral Challenge
|
|
Feb 14, 02
|
| 17:29 ET |
The Immune Response Corporation Announces Completion Of a $2 Million Private Financing
|
|
Nov 14, 01
|
| 07:00 ET |
The Immune Response Corporation Announces Third Quarter 2001 Financial Results
|
|
Nov 13, 01
|
| 07:01 ET |
The Immune Response Corporation Announces Completion of Private Financing
|
|
Aug 30, 01
|
| 07:00 ET |
The Immune Response Corporation Announces Its Decision Not to Proceed With Agouron's REMUNE(R) Study 202
|
|
| 03:00 ET |
Data Safety Monitoring Board Finds Primary Endpoint Met From Phase II Clinical Trial of REMUNE(R)
|
|
Aug 14, 01
|
| 07:02 ET |
The Immune Response Corporation Announces Second Quarter 2001 Financial Results
|
|
Jul 25, 01
|
| 07:01 ET |
The Immune Response Corporation Intends to Vigorously Defend Lawsuits
|
|
Jul 11, 01
|
| 17:14 ET |
New Virological Findings From Phase II Clinical Trial of REMUNE(TM) Presented at the 1st International AIDS Society Conference On HIV Pathogenesis and Treatment
|
|
Jul 06, 01
|
| 10:30 ET |
Agouron Pharmaceuticals, Inc. Terminates REMUNE(TM) Development Collaboration
|
|
Jun 01, 01
|
| 15:47 ET |
The Immune Response Corporation Reports Findings From Phase II Clinical Trial of REMUNE(TM) in HIV-Infected Patients
|
|
May 29, 01
|
| 07:00 ET |
The Immune Response Corporation Announces Additional Published Data Further Suggest Treatment With REMUNE(TM) May Stimulate CD8+ T Cell 'Killer' Function Against HIV
|
|
May 21, 01
|
| 07:00 ET |
Immunization With an HIV-1 Immunogen (REMUNE(TM)) Appears To Induce Allo-Responses and HIV-1 Specific Responses
|
|
May 08, 01
|
| 07:01 ET |
The Immune Response Corporation Announces First Quarter 2001 Financial Results
|
|
May 01, 01
|
| 09:15 ET |
The Immune Response Corporation Announces the Conversion and Proposed Redemption of Its Outstanding Shares of Series F Convertible Preferred Stock
|
|
Apr 30, 01
|
| 07:05 ET |
The Immune Response Corporation Announces Publication Of Data From a Previous Multiple Sclerosis Vaccine Study
|
|
Apr 27, 01
|
| 07:01 ET |
The Immune Response Corporation Names Dr. Elias Nyberg as Vice President, Regulatory Affairs
|
|
Apr 26, 01
|
| 06:57 ET |
The Immune Response Corporation Granted U.S. Patent for the Use of Antibodies To Target T Cell Receptors to Treat Rheumatoid Arthritis
|
|
Apr 23, 01
|
| 07:00 ET |
The Immune Response Corporation Announces Publication of Study Suggesting That REMUNE(TM) Induces HIV-1 Specific T Helper Immune Responses That Correlate With Control of Virus
|
|
Mar 30, 01
|
| 07:00 ET |
The Immune Response Corporation Is Granted U.S. Patent for DNA Vaccine Technology Related to Rheumatoid Arthritis
|
|
Mar 13, 01
|
| 07:05 ET |
The Immune Response Corporation Scientists Report Preliminary Results Of Structured Treatment Interruption Study in HIV-Positive Individuals
|
|
Mar 05, 01
|
| 07:01 ET |
The Immune Response Corporation Announces Investigational Vaccine Appears To Be Protective Against Tumor Development and Inhibits Spread of Pre-Existing Tumors in Animal Models
|
|
Feb 28, 01
|
| 07:00 ET |
The Immune Response Corporation Announces Fourth Quarter and Year-End 2000 Financial Results
|
|
Dec 18, 00
|
| 07:01 ET |
The Immune Response Corporation Acquires Partial Ownership of Privately Held MicroGenomics, Inc.
|
|
Nov 21, 00
|
| 07:02 ET |
Independent HIV Expert Committee Recommends Completion of Study of REMUNE(TM) Plus Antiretroviral Drugs in Order to Solidify the Findings
|
|
Nov 14, 00
|
| 07:02 ET |
The Immune Response Corporation Initiates Phase I/II Clinical Trial for Multiple Sclerosis
|
|
Nov 13, 00
|
| 07:00 ET |
The Immune Response Corporation Announces Third Quarter 2000 Financial Results
|
|
Oct 31, 00
|
| 07:02 ET |
The Immune Response Corporation Announces Arbitration Proceedings And Dispute Over Exclusion of Clinical Investigators and Sponsor Comments In The Publication of Clinical Trial Data Of REMUNE(TM) (HIV-1 Immunogen)
|
|
Sep 28, 00
|
| 07:01 ET |
The Immune Response Corporation Names Alan S. Rosenthal, M.D., as Board Member
|
|
Sep 19, 00
|
| 07:00 ET |
The Immune Response Corporation Announces the Addition of REMUNE(TM), An Investigational Therapeutic Vaccine for the Treatment of Primary HIV Infection, to the 'QUEST' Study
|
|
Aug 16, 00
|
| 07:00 ET |
The Immune Response Corporation Announces Exercise of Over-Allotment Option In Connection With Public Offering
|
|
Aug 10, 00
|
| 07:02 ET |
The Immune Response Corporation Announces Second Quarter 2000 Financial Results
|
|
Aug 09, 00
|
| 07:00 ET |
The Immune Response Corporation Granted U.S. Patent For Targeting and Vaccinating With T Cell Receptor Peptides
|
|
Aug 08, 00
|
| 07:03 ET |
The Immune Response Corporation Announces Public Offering of Its Common Stock
|
|
Jul 14, 00
|
| 07:02 ET |
Clinical Data on REMUNE(TM) (Investigational HIV-1 Immunogen) Selected as a Late Breaker Presentation at the XIII International AIDS Conference in Durban, South Africa
|
|
Jul 13, 00
|
| 07:01 ET |
Killer T Cells Against the AIDS Virus Appear to be Activated By Combination Treatment With REMUNE(TM) (Investigational HIV-1 Immunogen) and Antiviral Drugs
|
|
Jul 12, 00
|
| 08:02 ET |
The Immune Response Corporation Offers 2,400,000 Shares of Its Common Stock
|
|
Jun 21, 00
|
| 07:03 ET |
Interim Results in a Patient Subset Indicate That Treatment With REMUNE(TM) and Antiviral Drugs May Stimulate 'Killer' T Cell Activity
|
|
Jun 09, 00
|
| 07:00 ET |
The Immune Response Corporation and Agouron Pharmaceuticals, Inc. Announce ACTG Study Update
|
|
May 11, 00
|
| 07:01 ET |
The Immune Response Corporation Announces First Quarter 2000 Financial Results
|
|
May 10, 00
|
| 07:01 ET |
The Immune Response Corporation and Agouron Announce the Initiation Of a Pivotal Clinical Trial of REMUNE(TM), an Investigational Immune-Based Therapy for the Treatment of HIV Infection
|
|
Apr 13, 00
|
| 07:03 ET |
HIV Therapy With Remune(TM) Appears to Reconstitute Helper T-Cell Responses Against the Virus in Patients on Antiviral Drug Therapy
|
|
Mar 29, 00
|
| 07:00 ET |
The Immune Response Corporation to Pursue Development of a Potential Preventive HIV Vaccine
|
|
Mar 27, 00
|
| 13:24 ET |
The Immune Response Corporation Announces Progress in the Identification Of Genes Modulated During Spinal Cord Injury and Peripheral Nerve Regeneration
|
|
Mar 23, 00
|
| 07:01 ET |
Recent Clinical Data Suggest That REMUNE(TM) May Help to Rebuild Immune System When Used Alone or in Combination With Antiviral Drugs Against AIDS Virus
|
|
Mar 15, 00
|
| 07:02 ET |
The Immune Response Corporation Utilizes Functional Genomics to Identify Genes Associated With Processes of Nerve Growth and Repair
|
|
Mar 08, 00
|
| 07:02 ET |
The Immune Response Corporation and Cedars-Sinai Medical Center Initiate Enrollment for a Phase I Trial of a Potential New Vaccine Designed to Prevent The Recurrence of Brain Tumors
|
|
Mar 06, 00
|
| 07:00 ET |
The Immune Response Corporation Announces REMUNE(TM) Appears to Stimulate Broad Cross Reactive Immune Responses to Several Different Strains Of HIV & The Patient's Own Virus
|
|
Mar 02, 00
|
| 14:13 ET |
The Immune Response Corporation Announces Fourth Quarter And Year-End 1999 Financial Results
|
|
Feb 23, 00
|
| 07:03 ET |
The Immune Response Corporation Announces Results From A Phase II Clinical Trial of REMUNE in Thailand at The WHO-UNAIDS Vaccine Advisory Committee Meeting
|
|
Feb 22, 00
|
| 07:00 ET |
The Immune Response Corporation Announces Preclinical Results for A Genetically Engineered Cancer Vaccine
|
|
Feb 17, 00
|
| 07:02 ET |
The Immune Response Corporation Announces The Synthesis of a New Factor VIII Gene
|
|
Feb 10, 00
|
| 07:02 ET |
The Immune Response Corporation Receives Two U.S. Patents On Immunotherapeutics for Prevention and Treatment of Retroviral Disease
|
|
Jan 25, 00
|
| 07:03 ET |
The Immune Response Corporation Announces the Start of a Trial To Examine the Effects of REMUNE During Early-Stage HIV-Infection
|
|
Jan 18, 00
|
| 07:01 ET |
The Immune Response Corporation Announces A $5 Million Payment From Agouron Pharmaceuticals, Inc.
|
|
Dec 13, 99
|
| 07:31 ET |
The Immune Response Corporation Announces Acquisition Of T Cell Receptor Technology From Connetics and XOMA
|
|
Nov 23, 99
|
| 16:30 ET |
The Immune Response Corporation Announces the Completion Of the Sale of Common Stock to an Institutional Investor
|
|
Nov 15, 99
|
| 07:01 ET |
The Immune Response Corporation Presents Rheumatoid Arthritis Phase IIb Data Suggesting Positive Clinical Response to Proprietary Therapeutic Vaccine
|
|
Nov 04, 99
|
| 07:01 ET |
Data Safety Monitoring Board Recommends Completion of a Phase II Remune Trial in Spain of Patients Infected With HIV
|
|
Nov 03, 99
|
| 22:24 ET |
The Immune Response Corporation Presents Data Suggesting That Remune May Have an Effect on the Control of HIV Infection
|
|
Nov 02, 99
|
| 20:43 ET |
The Immune Response Corporation Announces Third Quarter 1999 Financial Results
|
|
Oct 22, 99
|
| 05:00 ET |
The Immune Response Corporation Announces Sale of $3 Million of Common Stock To Institutional Investor
|
|
Oct 18, 99
|
| 09:03 ET |
The Immune Response Corporation Announces Additional Restructuring
|
|
| 09:03 ET |
The Immune Response Corporation Announces a $5 Million Payment From Agouron Pharmaceuticals, Inc.
|
|
Oct 14, 99
|
| 07:00 ET |
The Immune Response Corporation Publishes Data in Proceedings of the National Academy of Sciences Suggesting a Correlation Between HIV-specific Immune Responses and Favorable Clinical Status
|
|
Oct 11, 99
|
| 07:00 ET |
The Immune Response Corporation Reports Investigational Colon Cancer Vaccine Phase 1 Trial Data in Clinical Cancer Research
|
|
Sep 27, 99
|
| 09:59 ET |
Agouron and Immune Response Initiate Pivotal Trial of REMUNE, An Immune-Based Therapy for the Treatment of HIV Infection
|
|
Sep 07, 99
|
| 07:01 ET |
Study of the Immune Response Corporation's Remune in Children Suggests Sustained Reduction of Viral Load
|
|
Aug 12, 99
|
| 07:02 ET |
The Immune Response Corporation Announces REMUNE Clinical Trial in South America
|
|
Aug 05, 99
|
| 07:02 ET |
The Immune Response Corporation Announces Second Quarter 1999 Financial Results
|
|
Jul 20, 99
|
| 09:00 ET |
The Immune Response Corporation Announces Filing Of Shelf Registration Statement
|
|
Jul 16, 99
|
| 07:01 ET |
The Immune Response Corporation Announces a $5 Million Payment From Agouron Pharmaceuticals, Inc.
|
|
Jun 21, 99
|
| 12:38 ET |
The Immune Response Corporation Announces Restructuring And Expense Reduction Plan
|
|
Jun 07, 99
|
| 07:00 ET |
The Immune Response Corporation Announces Organizational Changes
|
|
May 17, 99
|
| 07:01 ET |
Independent Panel Recommends Concluding Clinical Endpoint Trial of REMUNE; Agouron Pharmaceuticals, Inc. and The Immune Response Corporation To Pursue Alternative Regulatory Strategy
|
|
May 10, 99
|
| 14:38 ET |
The Immune Response Corporation and Institute of Human Virology to Collaborate to Develop and Commercialize Proprietary Technology From the University of Maryland Biotechnology Institute
|
|
May 05, 99
|
| 07:00 ET |
The Immune Response Corporation Announces First Quarter 1999 Financial Results
|
|
Apr 20, 99
|
| 07:01 ET |
Immune Response Announces $5 Million Quarterly Payment for Remune Collaboration From Agouron Pharmaceuticals, Inc.
|
|
Apr 15, 99
|
| 07:02 ET |
The Immune Response Corporation Announces U.S. Patent for Membrane-Bound Cytokine Compositions
|
|
Apr 05, 99
|
| 07:00 ET |
Howard Sampson, CPA, Joins the Immune Response Corporation as Executive Director, Finance and Controller
|
|
Mar 26, 99
|
| 07:00 ET |
The Immune Response Corporation Announces Data Safety Monitoring Board Meeting
|
|
Mar 02, 99
|
| 07:01 ET |
Rand P. Mulford Joins The Immune Response Corporation as Chief Financial Officer and Senior Vice President, Corporate Development
|
|
Feb 16, 99
|
| 07:00 ET |
The Immune Response Corporation Announces a $5 Million Milestone Payment From Agouron Pharmaceuticals, Inc.
|
|
Feb 02, 99
|
| 07:01 ET |
The Immune Response Corporation Receives U.S. Patent for the Treatment of T Cell Cancers
|
|
Jan 28, 99
|
| 07:01 ET |
The Immune Response Corporation Announces Fourth Quarter And Year-End 1998 Financial Results
|
|
Jan 19, 99
|
| 07:02 ET |
The Immune Response Corporation Announces a $5 Million Payment from Agouron
|
|
Dec 21, 98
|
| 07:00 ET |
IMNR Announces Results From Phase IIb Clinical Trial for Rheumatoid Arthritis
|
|
Dec 07, 98
|
| 08:04 ET |
IMNR Receives U.S. Patent on Rheumatoid Arthritis and Multiple Sclerosis Technologies
|
|
Dec 04, 98
|
| 13:30 ET |
IMNR Announces Resignation of Charles Cashion as Chief Financial Officer
|
|
Nov 24, 98
|
| 15:32 ET |
The Immune Response Corporation Announces Publication of Phase 2 Trial Results For Rheumatoid Arthritis Treatment
|
|
| 08:01 ET |
Margulies to Manage Corporate Communications/Investor Relations
|
|
Oct 29, 98
|
| 11:15 ET |
The Immune Response Corporation Announces Third Quarter 1998 Financial Results
|
|
Oct 26, 98
|
| 08:06 ET |
The Immune Response Corporation Announces REMUNE Clinical Data From Phase II Combination Drug Trial
|
|
Oct 19, 98
|
| 08:08 ET |
The Immune Response Corporation Receives First $5 million Quarterly Payment from Agouron Pharmaceuticals, Inc.
|
|
Sep 16, 98
|
| 08:02 ET |
The Immune Response Corporation Treats First Patient in Phase Ib Clinical Trial for Colon Cancer
|
|
Sep 09, 98
|
| 08:03 ET |
The Immune Response Corporation Presents Exploratory Phase II Clinical Trial Data on Psoriasis
|
|
Aug 25, 98
|
| 08:02 ET |
The Immune Response Corporation Announces Publication of Results from Thailand Clinical Trial
|
|
Aug 18, 98
|
| 08:04 ET |
The Immune Response Corporation Announces Initiation of Open-Label Clinical Trial of Rheumatoid Arthritis Treatment
|
|
Jul 23, 98
|
| 08:02 ET |
The Immune Response Corporation Announces Second Quarter 1998 Financial Results
|
|
Jul 09, 98
|
| 08:30 ET |
Schering-Plough and Immune Response in Agreement to Develop Hepatitis Gene Therapy Products
|
|
Jun 17, 98
|
| 08:03 ET |
The Immune Response Corporation Begins Additional Combination Drug Trial with REMUNE(TM) in the United States
|
|
Jun 11, 98
|
| 16:00 ET |
The Immune Response Corporation and Agouron Pharmaceuticals, Inc. Announce Collaboration to Commercialize REMUNE(TM)
|
|
Jun 09, 98
|
| 08:01 ET |
The Immune Response Corporation Announces Data Safety Monitoring Board Meeting on REMUNE(TM) Phase III Clinical Trial
|
|
Jun 02, 98
|
| 08:03 ET |
The Immune Response Corporation Announces Publication of Clinical Data Concerning Immune Responses in Individuals Treated with REMUNE(TM)
|
|
May 05, 98
|
| 08:02 ET |
The Immune Response Corporation Announces First Quarter 1998 Financial Results
|
|
Apr 30, 98
|
| 08:01 ET |
The Immune Response Corporation Announces Completion of $10 Million Private Placement
|
|
Apr 16, 98
|
| 08:02 ET |
The Immune Response Corporation Announces Publication of Preclinical Data on Potential Preventative HIV Vaccine
|
|
Mar 17, 98
|
| 09:21 ET |
The Immune Response Corporation Prevails in European Patent Opposition on Autoimmune Disease Technology
|
|
Mar 10, 98
|
| 08:01 ET |
The Immune Response Corporation Announces Initiation of REMUNE(TM) Clinical Trial in Great Britain
|
|
Feb 12, 98
|
| 08:01 ET |
The Immune Response Corporation Announces Favorable Results from the Thailand Clinical Trial
|
|
Feb 10, 98
|
| 08:05 ET |
The Immune Response Corporation Shows Treatment with REMUNE(TM) has a Favorable Impact on HIV Marker of Disease Progression
|
|
Jan 30, 98
|
| 08:00 ET |
The Immune Response Corporation Announces Fourth Quarter And Year-End 1997 Financial Results
|
|
Jan 27, 98
|
| 08:02 ET |
The Immune Response Corporation Announces Initiation of REMUNE(TM) Clinical Trial in Switzerland
|
|
Jan 22, 98
|
| 08:01 ET |
The Immune Response Corporation Announces REMUNE(TM) Activity Against Different Strains of HIV-1
|
|
Jan 14, 98
|
| 08:03 ET |
The Immune Response Corporation Reports New Data Supporting the Importance of Maintaining HIV-Specific Immune Function
|
|
Dec 04, 97
|
| 08:01 ET |
The Immune Response Corporation Announces Data Safety Monitoring Board Meeting on REMUNE(TM) Phase III Clinical Trial
|
|
Dec 02, 97
|
| 08:02 ET |
The Immune Response Corporation Treats First Patient in Phase IIb Clinical Trial Using Rheumatoid Arthritis Treatment
|
|
Nov 19, 97
|
| 08:02 ET |
The Immune Response Corporation Treats First Patient in Phase II Clinical Trial Using Psoriasis Treatment
|
|
Nov 11, 97
|
| 08:02 ET |
The Immune Response Corporation Presents Results from Phase II Clinical Trial For Rheumatoid Arthritis at American College of Rheumatology Annual Meeting
|
|
Oct 23, 97
|
| 08:00 ET |
The Immune Response Corporation Announces Third Quarter 1997 Financial Results
|
|
Oct 15, 97
|
| 08:01 ET |
The Immune Response Corporation Licensed Cancer Vaccine Technology Receives United States Patent
|
|
Sep 29, 97
|
| 08:05 ET |
The Immune Response Corporation Receives Final Payment of $12 Million From Private Placement
|
|
Sep 22, 97
|
| 08:00 ET |
The Immune Response Corporation Presents REMUNE(TM) Data at the Second Annual Institute of Human Virology Meeting
|
|
Jul 24, 97
|
| 08:03 ET |
The Immune Response Corporation Announces Second Quarter 1997 Financial Results
|
|
Jul 09, 97
|
| 08:16 ET |
The Immune Response Corporation Publishes Additional Findings On T Cells Involved in Psoriasis
|
|
Jun 25, 97
|
| 08:03 ET |
The Immune Response Corporation Publishes Results From Phase I Multiple Sclerosis Clinical Trial
|
|
May 12, 97
|
| 08:04 ET |
The Immune Response Corporation Completes Enrollment of 2,500 Patient Phase III Clinical Trial of REMUNE(TM)
|
|
Apr 24, 97
|
| 08:07 ET |
The Immune Response Corporation Announces First Quarter 1997 Financial Results
|
|
Apr 21, 97
|
| 08:05 ET |
Insiders Complete $15.8 Million Private Placement in the Immune Response Corporation
|
|
Apr 15, 97
|
| 08:00 ET |
The Immune Response Corporation Reports New Antiviral Activity Using REMUNE(TM)
|
|
Mar 19, 97
|
| 08:03 ET |
The Immune Response Corporation Receives United States Patent on Autoimmune Disease Technology
|
|
Feb 12, 97
|
| 08:05 ET |
The Immune Response Corporation Begins Phase II Clinical Trial Using Combination of Antiviral Drugs and REMUNE(TM)
|
|
Feb 11, 97
|
| 08:02 ET |
The Immune Response Corporation Announces Fourth Quarter and Year-End 1996 Financial Results
|
|
Jan 31, 97
|
| 08:01 ET |
The Immune Response Corporation Presents REMUNE(TM) Data on Chemokines At Scientific Meeting
|
|
Jan 07, 97
|
| 08:04 ET |
The Immune Response Corporation Announces Results From Phase II Clinical Trials for Rheumatoid Arthritis and Psoriasis
|
|
Dec 10, 96
|
| 12:01 ET |
The Immune Response Corporation Initiates Collaboration with the University of California, Los Angeles to Develop Brain Cancer Vaccine
|
|
Nov 07, 96
|
| 08:01 ET |
The Immune Response Corporation Announces Combination Drug Trial Using REMUNE(TM) in Collaboration with Glaxo and Merck
|
|
Nov 05, 96
|
| 08:01 ET |
The Immune Response Corporation Announces Exercise of Over-Allotment Option for Public Offering of Common Stock
|
|
Nov 04, 96
|
| 08:00 ET |
The Immune Response Corporation Announces Third Quarter 1996 Financial Results
|
|
Oct 31, 96
|
| 08:02 ET |
The Immune Response Corporation Announces Clinical Trial in Spain Using REMUNE(TM)
|
|
Oct 28, 96
|
| 09:46 ET |
The Immune Response Corporation Makes Public Offering of 2,200,000 Shares of Common Stock
|
|
Oct 14, 96
|
| 08:02 ET |
The Immune Response Corporation Announces Expanded Access Program of REMUNE(TM) to Treat HIV Infection
|
|
Oct 08, 96
|
| 08:02 ET |
The Immune Response Corporation Signs Agreement with Viru-Tech Limited for REMUNE(TM) in South America and Central America
|
|
Oct 01, 96
|
| 08:02 ET |
The Immune Response Corporation Receives United States Patent Office Notice of Allowance for Licensed Cancer Technology
|
|
Sep 24, 96
|
| 08:02 ET |
The Immune Response Corporation Announces Publication of REMUNE(TM) Clinical Trial Data
|
|
Sep 17, 96
|
| 08:09 ET |
The Immune Response Corporation Reports First Interim Analysis of Phase II Clinical Trial Data Using REMUNE(TM) in Thailand by Trinity Medical Group
|
|
Sep 11, 96
|
| 08:03 ET |
Rheumatoid Arthritis Results Published from Phase I Clinical Trial Conducted by The Immune Response Corporation
|
|
Aug 07, 96
|
| 08:03 ET |
The Immune Response Corporation Postpones Follow-on Public Offering of Common Stock
|
|
Jul 19, 96
|
| 19:00 ET |
THE IMMUNE RESPONSE CORPORATION ANNOUNCES SECOND QUARTER 1996 FINANCIAL RESULTS
|
|